We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+3.64%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$74.9B
AUM Growth
+$9.23B
Cap. Flow
+$7.27B
Cap. Flow %
9.7%
Top 10 Hldgs %
32.66%
Holding
3,137
New
748
Increased
792
Reduced
857
Closed
654

Top Buys

Rank Stock Value
1
IVV icon
iShares Core S&P 500 ETF
IVV
+$3.04B
2
MSFT icon
Microsoft
MSFT
+$830M
3
AMZN icon
Amazon
AMZN
+$550M
4
JNJ icon
Johnson & Johnson
JNJ
+$483M
5
AAPL icon
Apple
AAPL
+$470M

Sector Composition

Rank Sector Weight
1 Technology 18.7%
2 Consumer Discretionary 13.75%
3 Healthcare 12.4%
4 Financials 7.81%
5 Industrials 6.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
K
201
DELISTED
Kellanova
K
$72.6M 0.1%
1,258,929
-607,746
-33% -$35.9M
SONY icon
202
Sony
SONY
$123B
$72.1M 0.1%
4,242,070
+4,192,715
+8,495% +$69.3M
SLV icon
203
PUT
iShares Silver Trust
SLV
$28.1B
$69M 0.09%
2,597,400
+2,496,100
+2,464% +$65.7M
AMP icon
204
Ameriprise Financial
AMP
$46.8B
$68.5M 0.09%
160,465
-197,395
-55% -$84.3M
COO icon
205
Cooper Companies
COO
$13.7B
$68.4M 0.09%
783,897
-799,998
-51% -$74.7M
CAG icon
206
Conagra Brands
CAG
$7.07B
$68.4M 0.09%
2,406,743
+2,242,186
+1,363% +$67.4M
M icon
207
Macy's
M
$6.15B
$67.9M 0.09%
3,534,952
+3,319,337
+1,539% +$63.4M
TEVA icon
208
Teva Pharmaceuticals
TEVA
$35.9B
$67.8M 0.09%
4,172,593
-42,623
-1% -$657K
MDB icon
209
MongoDB
MDB
$24B
$67.2M 0.09%
268,958
-337,490
-56% -$107M
TDW icon
210
Tidewater
TDW
$3.91B
$67M 0.09%
704,176
-67,257
-9% -$6.63M
XP icon
211
XP
XP
$8.62B
$66.4M 0.09%
3,775,923
+432,116
+13% +$8.93M
FIVE icon
212
Five Below
FIVE
$11.2B
$66M 0.09%
605,703
+207,083
+52% +$28.7M
HLT icon
213
Hilton Worldwide
HLT
$74B
$66M 0.09%
+302,290
New +$62.1M
TT icon
214
Trane Technologies
TT
$106B
$65.7M 0.09%
199,664
+81,598
+69% +$26M
GMED icon
215
Globus Medical
GMED
$10.4B
$65.6M 0.09%
957,734
-271,706
-22% -$16.2M
QCOM icon
216
Qualcomm
QCOM
$176B
$65.5M 0.09%
329,000
+303,291
+1,180% +$57.3M
EEM icon
217
iShares MSCI Emerging Markets ETF
EEM
$28B
$65.2M 0.09%
1,529,815
+361,284
+31% +$15.2M
TOST icon
218
Toast
TOST
$16.8B
$64.9M 0.09%
2,517,288
+1,604,716
+176% +$38.8M
FCX icon
219
Freeport-McMoran
FCX
$90B
$64.3M 0.09%
1,323,508
-137,532
-9% -$6.93M
SCHW
220
Charles Schwab
SCHW
$177B
$64.1M 0.09%
869,667
-322,300
-27% -$23.8M
CI icon
221
Cigna
CI
$76.6B
$63.8M 0.09%
+193,000
New +$66.6M
GEHC icon
222
GE HealthCare
GEHC
$27.6B
$63.6M 0.09%
+816,728
New +$66.6M
C icon
223
PUT
Citigroup
C
$222B
$62.7M 0.08%
987,800
-343,300
-26% -$21.2M
MU icon
224
Micron Technology
MU
$1.04T
$62.2M 0.08%
473,163
-2,186,212
-82% -$275M
DT icon
225
Dynatrace
DT
$12.1B
$62.2M 0.08%
1,389,727
+1,029,387
+286% +$47.4M

Similar funds

Marshall Wace's Q2 2024 Portfolio in Review

As of Q2 2024, Marshall Wace held 3,137 positions worth $74.9B, up 14% from $65.7B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Marshall Wace deployed $7.27B of net new capital in Q2 2024, opening 748 new positions and adding to 792 existing holdings. Its largest new stake was GE Vernova: 2,330,887 shares worth $400M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Procter & Gamble, an estimated $474M trimmed.

  • Marshall Wace's largest Q2 2024 buy was GE Vernova: 2,330,887 shares worth $400M.
  • Marshall Wace added most to iShares Core S&P 500 ETF in Q2 2024, an estimated $3.04B increase.
  • Marshall Wace's biggest Q2 2024 reduction was Procter & Gamble, cutting an estimated $474M.
  • Marshall Wace fully exited Applied Materials in Q2 2024, selling an estimated $127M.
  • Marshall Wace's ten largest holdings make up 33% of its $74.9B portfolio in Q2 2024.
  • Marshall Wace opened 748 new positions and closed 654 in Q2 2024.
  • Marshall Wace's portfolio value rose 14% quarter-over-quarter to $74.9B.

Based on Marshall Wace's 13F filing for Q2 2024, filed 14 Aug 2024.